The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

The findings were in line with those of a large retrospective cohort study that showed that patients treated with GLP-1 ...

A product development expert explains how the swift rise of these anti-obesity medications is fueling new food trends.

South Africa's Aspen Pharmacare has started registering GLP-1 drugs used to treat diabetes and obesity in markets where ...

Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

You've probably seen the ads for GLP-1 drugs. It's a hormone that helps people lose weight, but the results are not ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

GLP-1 medications like Ozempic are reshaping the way people snack, with fewer ultra-processed foods and a shift toward nutrient-packed bites. See what’s in and what’s out.